[Archives de la Parole]. , From Dole Lila [Dole Lila : Bahiye Bahiye Jai] (Bengali Band) / Frederick William Gaisberg, collecteur ; Classic Theatre Concert Co. [i.e. Classic Theatre Concert Company Band], orchestre

[Traditions. Asie. Inde]

[Archives de la Parole]. , Monologue (Diction) : Premier disque à aiguille enregistré électriquement le 28 janvier 1925 / Voix parlée homme ; M. Rousseau, piano. Orchestre enregistré électriquement le 28 juillet 1926 / orchestre

Enregistrement : (France) [Studio Bernard Roux, Paris], 28-01-1925 - 28-07-1926

[Archives de la Parole]. , Diction [Ecole internationale: phonogramme de français N°2] ; Diction [Ecole internationale: phonogramme de français N°3] / Voix homme

Enregistrement : (France) [Studio Bernard Roux, Paris], -.]-[s.d

[Archives de la Parole]. , Luma namthar : Tibetan Duet / Wangdi, chant duo. Sonam Panguay : Tibetan Song / Nima, chant

Langue tibétaine

[Archives de la Parole]. , Sindhu (Bengali Song) / William Sinkler Darby, collecteur ; Debendro Nath Banerjee [i.e. Babu Dejendra Nath Banerjee], chant ; accompagnement instrumental (harmonium indien)

[Traditions. Asie. Inde]

[Archives de la Parole]. , Jhijit khambag (Bengali Song) / William Sinkler Darby, collecteur ; Abdool Gafoor [i.e. Ustad Abdul Gafur], chant ; accompagnement instrumental (harmonium indien, tablâ, flûte)

[Traditions. Asie. Inde]

[Archives de la Parole]. , Parable of the prodigal son in Kanarese : [from Dharwar] / [Sir George Grierson], éd. ; Linguistic survey of India ; [G.G. Kulkarni], voix

[Traditions. Asie. Inde. Etat du Karnataka. Dharwad]

[Archives de la Parole]. , Parabole de l'enfant prodigue : en marathi - Indo-aryen / [Sir George Grierson], éd. ; Linguistic survey of India ; [S.B. Naik], voix

[Traditions. Asie. Inde. État du Maharashtra. Dhule]

[Archives de la Parole]. , Parabole de l'enfant prodigue : parjé, groupe central, indo-aryen / [Sir George Grierson], éd. ; Linguistic survey of India ; [R.G. Haridas], voix

[Traditions. Asie. Inde. Etat du Karnataka. Kanara]

[Archives de la Parole]. , Parabole de l'enfant prodigue : en shindi - groupe occidental, Indo-aryen / [Sir George Grierson], éd. ; Linguistic survey of India ; [V.T. Shimpi], voix

[Traditions. Asie. Inde. État du Maharashtra. Dhule]

[Archives de la Parole]. , [Bheeshma's vow] : dialecte Canara [i.e. Kannara], langues dravidiennes, Province de Bombay / [Sir George Grierson], éd. ; Linguistic survey of India ; [B.B. Burli], voix

[Traditions. Asie. Inde. État du Karnataka. Bîjâpur]

[Archives de la Parole]. , [Parable of the prodigal son in Gujarātī] / [Sir George Grierson], éd. ; Linguistic survey of India ; [Someshvar Dhirajram], voix

[Traditions. Asie. Inde. État du Gujarat. Ahmadabad]

Long-term outcome of primary endoresection of choroidal melanoma.

BACKGROUND: Endoresection of choroidal melanoma may offer the best hope of conserving vision in some patients but is controversial because of concerns regarding iatrogenic tumour dissemination. METHODS: Retrospective, non-randomised study of consecutive patients who underwent endoresection for choroidal melanoma at the Liverpool Ocular Oncology Centre between 1996 and 2010. RESULTS: The study included 71 patients with a mean age of 58.7 years. The tumour extended within 2 disc diameters of the optic disc in 46 (65%) eyes, involving the disc in 24 (34%) eyes. The mean largest basal tumour diameter and tumour thickness were 9.5 mm and 4.4 mm, respectively. The median follow-up was 4.1 years. The visual acuity at the latest follow-up was better than 6/30 in 31% eyes. The main causes of visual loss were foveal excision, rhegmatogenous retinal detachment (RD) and proliferative vitreo-retinopathy (PVR). Local recurrence developed in two patients (3%), who were treated by enucleation and proton beam radiotherapy, respectively. RD occurred in 16 cases (22%). Three (4%) eyes were enucleated, two because of PVR and one because of local tumour recurrence. Five patients died of metastatic disease. CONCLUSIONS: Endoresection achieved high rates of local tumour control. This operation would seem to be a useful alternative to radiotherapy as a means of conserving vision in eyes with juxtapapillary melanoma.

Fluorescein and indocyanine-green angiography in ocular syphilis: an exploratory study.

BACKGROUND: Fluorescein (FA) and indocyanine-green angiography (ICGA) may offer valuable information concerning disease severity and prognosis in ocular syphilis. The aim of the present study is to describe angiographic patterns encountered in the context of ocular syphilis, and to explore the associations between specific angiographic manifestations and severity of disease presentation, as well as disease evolution after treatment. METHODS: We performed a retrospective institutional study with the inclusion of 23 patients with ocular syphilis presenting to the uveitis clinic of the Jules-Gonin Eye Hospital in a 10-year period. FA and ICGA were performed following a standard protocol for posterior uveitis. Patterns of fluorescence were noted, and statistical associations between each angiographic pattern and any demographic, clinical, or laboratory parameter at baseline and after treatment were sought. RESULTS: The presence of any dark dots in ICGA was significantly associated with anterior uveitis (p = 0.031). The presence of hot spots in ICGA was significantly associated with longer duration of symptoms prior to initial visit (p = 0.032) and with male gender (p = 0.012). Weak non-significant trends were found associating vascular staining in FA with anterior uveitis (p = 0.066), vitritis (p = 0.069), and younger age (p = 0.061), as well as disc hyperfluorescence in FA with seropositivity for HIV (p = 0.089) and macular edema in FA with longer disease duration (p = 0.061). The presence of any dark dots in ICGA exhibited a weak trend of association with anterior uveitis and/or vitritis (p = 0.079). CONCLUSIONS: Out of the several associations identified implicating specific angiographic features, we underline the possible role of the presence of dark dots in ICGA for identifying active inflammation, and the role of hot spots in ICGA as markers of long-standing disease. Vascular staining in FA appears to be more common in patients with severe ocular inflammation with presence of anterior uveitis and/or vitritis.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

OBJECTIVE: To evaluate the relative efficacy and safety profile of bevacizumab versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration (AMD). DESIGN: Multicenter, prospective, noninferiority, double-masked, randomized clinical trial performed in 38 French ophthalmology centers. The noninferiority limit was 5 letters. PARTICIPANTS: Patients aged ≥50 years were eligible if they presented with subfoveal neovascular AMD, with best-corrected visual acuity (BVCA) in the study eye of between 20/32 and 20/320 measured on the Early Treatment of Diabetic Retinopathy Study chart and a lesion area of less than 12 optic disc areas (DA). METHODS: Patients were randomly assigned to intravitreal administration of bevacizumab (1.25 mg) or ranibizumab (0.50 mg). Hospital pharmacies were responsible for preparing, blinding, and dispensing treatments. Patients were followed for 1 year, with a loading dose of 3 monthly intravitreal injections, followed by an as-needed regimen (1 injection in case of active disease) for the remaining 9 months with monthly follow-up. MAIN OUTCOME MEASURES: Mean change in visual acuity at 1 year. RESULTS: Between June 2009 and November 2011, 501 patients were randomized. In the per protocol analysis, bevacizumab was noninferior to ranibizumab (bevacizumab minus ranibizumab +1.89 letters; 95% confidence interval [CI], -1.16 to +4.93, P < 0.0001). The intention-to-treat analysis was concordant. The mean number of injections was 6.8 in the bevacizumab group and 6.5 in the ranibizumab group (P = 0.39). Both drugs reduced the central subfield macular thickness, with a mean decrease of 95 μm for bevacizumab and 107 μm for ranibizumab (P = 0.27). There were no significant differences in the presence of subretinal or intraretinal fluid at final evaluation, dye leakage on angiogram, or change in choroidal neovascular area. The proportion of patients with serious adverse events was 12.6% in the bevacizumab group and 12.1% in the ranibizumab group (P = 0.88). The proportion of patients with serious systemic or ocular adverse events was similar in both groups. CONCLUSIONS: Bevacizumab was noninferior to ranibizumab for visual acuity at 1 year with similar safety profiles. Ranibizumab tended to have a better anatomic outcome. The results are similar to those of previous head-to-head studies. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.